Similar articles

• [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].

  Shimada H, Miki T, Kyogoku I, Kawagishi T, Inaba M, Okuno Y, Nishizawa Y, Morii H. Shimada H, et al. No To Shinkei. 1998 Sep;50(9):817-20. No To Shinkei. 1998. PMID: 9789304 Japanese.
• Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.

  Kawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M, Hirata T, Saruta T, Shimada A, Itoh H. Kawai T, et al. J Diabetes Complications. 2010 Nov-Dec;24(6):424-32. doi: 10.1016/j.jdiacomp.2008.10.005. Epub 2009 Aug 27. J Diabetes Complications. 2010. PMID: 19716319 Clinical Trial.
• Effects of aldose reductase inhibitor on the peripheral nerve function during ischemia in diabetics.

  Kuriya N, Miyake S, Yokota A, Yamaguchi Y, Nakanishi T, Takahashi A, Ueda Y, Mori T, Akiguchi I, Toyama K, et al. Kuriya N, et al. J Med Assoc Thai. 1987 Mar;70 Suppl 2:168-72. J Med Assoc Thai. 1987. PMID: 3110345 No abstract available.
• Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.

  Schemmel KE, Padiyara RS, D'Souza JJ. Schemmel KE, et al. J Diabetes Complications. 2010 Sep-Oct;24(5):354-60. doi: 10.1016/j.jdiacomp.2009.07.005. Epub 2009 Sep 11. J Diabetes Complications. 2010. PMID: 19748287 Review.
• Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.

  Ramirez MA, Borja NL. Ramirez MA, et al. Pharmacotherapy. 2008 May;28(5):646-55. doi: 10.1592/phco.28.5.646. Pharmacotherapy. 2008. PMID: 18447661 Review.